Syngene International has announced that Siddharth Mittal has assumed charge as the company's managing director (MD) and chief executive officer (CEO) with effect from 1 July 2026. According to reports from Business Standard, he succeeds Peter Bains, who completed his tenure as MD & CEO on 30 June 2026. As per Syngene, the leadership transition follows a period in which the company established scientific capabilities and customer relationships globally, with the new CEO expected to focus on commercial execution, customer fulfillment, and long-term growth. In his resignation letter to the chairman of the company's board, Bains said he is resigning from his position following "our recent discussions regarding leadership succession and CEO transition".
Kiran Mazumdar-Shaw, Executive Chairperson of Syngene International, expressed confidence in Mittal's appointment, stating that "I am delighted to welcome Siddharth as the Managing Director and CEO of Syngene. Having worked closely with Siddharth for many years, I have seen first hand his ability to lead businesses through period of change, build strong teams and deliver transformation and sustainable growth." As per PRNewswire, Mittal emphasized his immediate priorities, stating that "I am honoured to take on the role of Managing Director and CEO of Syngene. My immediate priority is to sharpen our commercial edge, strengthen delivery excellence and bring greater focus and discipline to execution across the business." According to Syngene, Mittal's appointment supports the company's next phase of growth as customer expectations and industry requirements continue to evolve.
As reported by Business Standard, Siddharth Mittal joins Syngene from Biocon, where he most recently served as managing director and CEO. During his 13-year tenure at Biocon, he also served as chief financial officer (CFO) before taking over as MD & CEO. At Biocon, he played a key role in shaping the company's long-term strategy, strengthening commercial operations, expanding its global presence, securing key regulatory approvals, commercializing Biocon's GLP-1 portfolio across major international markets, and driving strategic partnerships and operational excellence. According to Syngene, Mittal's appointment brings nearly three decades of leadership experience to the global CRDMO company, with his experience in commercial operations, strategic partnerships, and business transformation expected to help strengthen contract manufacturing and research services while enhancing execution and customer focus.
According to Business Standard, Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company's consolidated net profit declined 19.31% to ₹147.90 crore on a 1.82% rise in revenue from operations to ₹1,036.50 crore in Q4 FY26 over Q4 FY25. As per latest market data, Syngene International has a market capitalization of ₹17,416 crore and is trading at 3.70 times its book value. The company has delivered a poor sales growth of 9.45% over the past five years and maintains a low return on equity of 9.70% over the last 3 years. The stock has experienced a 32.2% decline in value over the past year.
As reported by Business Standard, shares of Syngene International fell 1.83% to close at ₹431.55 on the BSE following the leadership announcement. The market reaction reflects investor response to the change in top management leadership. According to latest market data, Syngene International shares are trading at ₹431.55 with the company having 400+ active customers and engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and maintains a base of 6,000+ scientists across its research and manufacturing infrastructure spread across 1.9 million square feet.
